Thomas Steyer’s Nuvation Bio NUVB Stock Holding History

Thomas Steyer’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,000	Closed	-$124K	–	153
2026 Q1	$124K	Hold	29,000	–	–	﹤0.01%	160
2025 Q4	$260K	Buy	+29,000	New	+$180K	﹤0.01%	120
2023 Q2	–	Sell	-1,465,000	Closed	-$2.43M	–	179
2023 Q1	$2.43M	Sell	1,465,000 -652,600	-31%	-$1.32M	0.01%	135
2022 Q4	$4.07M	Sell	2,117,600 -782,400	-27%	-$1.58M	0.02%	156
2022 Q3	$6.5M	Hold	2,900,000	–	–	0.04%	166
2022 Q2	$9.4M	Hold	2,900,000	–	–	0.05%	141
2022 Q1	$15.3M	Buy	2,900,000 +1,470,000	+103%	+$8.26M	0.07%	112
2021 Q4	$12.2M	Sell	1,430,000 -780,000	-35%	-$7.17M	0.06%	117
2021 Q3	$22M	Sell	2,210,000 -288,600	-12%	-$2.62M	0.1%	98
2021 Q2	$23.3M	Sell	2,498,600 -1,400	-0.1%	-$16K	0.1%	95
2021 Q1	$26.1M	Hold	2,500,000	–	–	0.13%	93
2020 Q4	$29.3M	Buy	+2,500,000	New	+$26M	0.18%	81

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Thomas Steyer's NUVB Position: Q2 2026 in Review

Thomas Steyer sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 29,000 shares — an estimated $124K sold.

Thomas Steyer first reported a position in NUVB in Q4 2020 and held it in 12 quarters. The position peaked at $29.3M in Q4 2020. 242 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Thomas Steyer reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 29,000 Nuvation Bio shares in Q2 2026, an estimated $124K.
Thomas Steyer first reported a position in Nuvation Bio in Q4 2020 and held it in 12 quarters.
Thomas Steyer's Nuvation Bio position peaked at $29.3M in Q4 2020.
242 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.